Ontogeny of renal P-glycoprotein expression in mice: Correlation with digoxin renal clearance

Pediatric Research

Volumn 58, Issue 6, 2005, Pages 1284-1289

  Pinto, Natasha ^a,b   Halachmi, Naomi ^a   Verjee, Zulfikarali ^a   Woodland, Cindy ^b   Klein, Julia ^a   Koren, Gideon ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DIGOXIN; GLYCOPROTEIN P; RNA; ABC TRANSPORTER; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 3; P GLYCOPROTEIN 2; P-GLYCOPROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; DNA SYNTHESIS; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; KIDNEY CLEARANCE; KIDNEY MASS; MOUSE; NEWBORN; NONHUMAN; ONTOGENY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; AGE; ANIMAL; GENETICS; KIDNEY; METABOLIC CLEARANCE RATE; METABOLISM; ORGAN SIZE;

AGE FACTORS; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BODY WEIGHT; DIGOXIN; KIDNEY; METABOLIC CLEARANCE RATE; MICE; ORGAN SIZE; P-GLYCOPROTEINS; RNA, MESSENGER;

EID: 33644796490     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/01.pdr.0000188697.99079.27     Document Type: Article

References (34)

1. Kauffman RE 2005 Drug action and therapy in infants and children. In: Yaffe SJ, Aranda JV (eds) Neonatal and pediatric pharmacology. Lippincott Williams and Wirkins, Philadelphia, pp 20-31
2. Morselli PL 1975 Digoxin pharmacokinetics during human development. In: Morselli PL, Garattini S, Sereni F (eds) Basic and therapeutic aspects of perinatal pharmacology. Raven Press, New York, pp 377-392
3. Nyberg L, Wettrell G 1978 Digoxin dosage schedules for neonates and infants based on pharmacokinetic considerations. Clin Pharmacokinet 3:453-461
4. Bendayan R 1996 Renal drug transport: a review. Pharmacotherapy 16:971-985
5. Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P, Housman DE 1989 The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 9:1346-1350
6. Devault A, Gros P 1990 Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 10:1652-63
7. Hsu SI, Lothstein L, Horwitz SB 1989 Differential overexpression of three mdr gene family members in multidrug-resistant J774.2 mouse cells. Evidence that distinct P-glycoprotein precursors are encoded by unique mdr genes. J Biol Chem 264:12053-12062
8. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP 1994 Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502
9. Gros P, Raymond M, Bell J, Housman D 1988 Cloning and characterization of a second member of the mouse mdr gene family. Mol Cell Biol 8:2770-2778
10. Schiengold M, Schwantes L, Schwartsmann G, Chies JA, Nardi NB 2001 Multidrug resistance gene expression during the murine ontogeny. Mech Ageing Dev 122:255-270
11. Kawahara M, Sakata A, Miyashita T, Tamai I, Tsuji A 1999 Physiologically based pharmacokinetics of digoxin in mdrla knockout mice. J Pharm Sci 88:1281-1287
12. Stephens RH, O'Neill CA, Bennett J, Humphrey M, Henry B, Rowland M, Warhurst G 2002 Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdrla (-/-) mice. Br J Pharmacol 135:2038-2046
13. Mahmood B, Daood MJ, Hart C, Hansen TW, Watchko JF 2001 Ontogeny of P-glycoprotein in mouse intestine, liver, and kidney. J Investig Med 49:250-257
14. Tsuruoka S, Sugimoto KI, Fujimura A, Imai M, Asano Y, Muto S 2001 P-glycoprotein-mediated drug secretion in mouse proximal tubule perfused in vitro. J Am Soc Nephrol 12:177-181
15. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM 1999 Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99:552-557
16. De Lannoy IA, Koren G, Klein J, Charuk J, Silverman M 1992 Cyclosporin and quinidine inhibition of renal digoxin excretion: evidence for luminal secretion of digoxin. Am J Physiol 263:F613-F622
17. Ito S, Woodland C, Harper PA, Koren G 1993 P-glycoprotein-mediated renal tubular secretion of digoxin: the toxicological significance of the urine-blood barrier model. Life Sci 53:PL25-PL31
18. Koren G, Woodland C, Ito S 1998 Toxic digoxin-drug interactions: the major role of renal P-glycoprotein. Vet Hum Toxicol 40:45-46
19. Woodland C, Ito S, Koren G 1998 A model for the prediction of digoxin-drug interactions at the renal tubular cell level. Ther Drug Monit 20:134-138
20. Woodland C, Koren G, Ito S 2003 From bench to bedside: utilization of an in vitro model to predict potential drug-drug interactions in the kidney: the digoxinmifepristone example. J Clin Pharmacol 43:743-750
21. Dutt A, Priebe TS, Teeter LD, Kuo MT, Nelson JA 1992 Postnatal development of organic cation transport and mdr gene expression in mouse kidney. J Pharmacol Exp Ther 261:1222-1230
22. Rosati A, Maniori S, Decorti G, Candussio L, Giraldi T, Bartoli F 2003 Physiological regulation of P-glycoprotein, MRP1, MRP2 and cytochrome P450 3A2 during rat ontogeny. Dev Growth Differ 45:377-387
23. Taipalensuu J, Tavelin S, Lazorova L, Svensson AC, Artursson P 2004 Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activity. Eur J Pharm Sci 21:69-75
24. Tanigawara Y 2000 Role of P-glycoprotein in drug disposition. Ther Drug Monit 22:137-140
25. Rane A 2005 Drug metabolism and disposition in infants and children. In: Yaffe SJ, Aranda JV (eds) Neonatal and pediatric pharmacology. Lippincott Williams and Wilkins, Philadelphia, pp 32-43
26. Noe B, Hagenbuch B, Stieger B, Meier PJ 1997 Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc Natl Acad Sci USA 94:10346-10350
27. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, Abe M, Satoh F, Unno M, Hishinuma T, Inui K, Ito S, Goto J, Abe T 2004 Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci USA 101:3569-3574
28. Potter EL 1965 Development of the human glomerulus. Arch Pathol 80:241-255
29. West JR, Smith HW, Chasis H 1948 Glomerular filtration rate, effective renal blood flow and maximal tubular excretory capacity in infancy. J Pediatr 32:10-18
30. Alcom J, McNamara PJ 2002 Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet 41:959-998
31. Morselli PL, Franco-Morselli R, Bossi L 1980 Clinical pharmacokinetics in newborns and infants: Age-related differences and therapeutic implications. Clin Pharmacokinet 5:485-527
32. Lothstein L, Hsu SI, Horwitz SB, Greenberger LM 1989 Alternate overexpression of two P-glycoprotein [corrected] genes is associated with changes in multidrug resistance in a J774.2 cell line. J Biol Chem 264:16054-16058
33. Yang JM, Sullivan GF, Hait WN 1997 Regulation of the function of P-glycoprotein by epidermal growth factor through phospholipase C. Biochem Pharmacol 53:1597-1604
34. Chen C, Liu X, Smith BJ 2003 Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development. Curr Drug Metab 4:272-291